The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
 
Zhengfu Fan
No Relationships to Disclose
 
Jin Wang
No Relationships to Disclose
 
Meiyu Fang
No Relationships to Disclose
 
Jilong Yang
No Relationships to Disclose
 
Yun Yang
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Qiuying Ma
No Relationships to Disclose
 
Jinming Han
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche; Sanofi
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); CANbridge Pharmaceuticals (Inst); Jacobio (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)